Article Figures & Data
Figures
- FIGURE 1.
A 63-y-old patient with biochemical recurrence (PSA of 0.21 ng/mL) after radical prostatectomy (initially pT2c N0 M0 L1/V1 R1 G1, Gleason score of 7), local radiation treatment, and antiandrogen therapy. 68Ga-PSMA ligand PET/CT exhibits solitary left iliac radiotracer-positive lymph node (arrow). Shown are transaxial CT (A), PET (B), and fused PET/CT (C) images. Patient was referred for salvage lymph node dissection.
- FIGURE 2.
A 78-y-old patient with biochemical recurrence (PSA of 0.54 ng/mL) after radical prostatectomy (initially pT3b N0 M0 R0 G2). 68Ga-PSMA ligand PET/CT reveals focal uptake in left paramedian prostatic fossa, indicating local recurrence. Shown are transaxial CT (A), PET (B), and fused PET/CT (C) images. Patient was referred for salvage radiation treatment.
- FIGURE 3.
Maximum-intensity-protection images (acquired with 18F-DCFBC [A] and 18F-DCFPyL [B]) displaying typical PSMA ligand biodistribution. Physiologic accumulation is seen in lacrimal and salivary glands, nasal mucosa, liver, spleen, bowel, kidneys, ureter on right side, and bladder.
- FIGURE 4.
Transaxial CT (A), PET (B), and fused PET/CT (C) 68Ga-PSMA ligand scans demonstrating moderate, focal PSMA ligand uptake (arrows) in comma-shaped soft-tissue structure between left adrenal gland and aorta, indicating normal variant uptake in celiac ganglion.
- FIGURE 5.
68Ga-PSMA ligand PET/CT scan exhibiting moderate, focal PSMA ligand uptake in left rib on transaxial PET (B) and fused PET/CT (D) images. (A and C) Corresponding CT images confirm minimally displaced fracture of rib.
Additional Files
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Additive Value of [68Ga]Ga-RM26 PET/CT to [68Ga]Ga-PSMA-617 PET/CT in Detecting Pelvic Lymph Node Metastasis in Prostate Cancer: A Prospective, Single-Center, Phase II Study
- Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study
- Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3
- Disparities in PET Imaging for Prostate Cancer at a Tertiary Academic Medical Center
- Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer
- Multiphasic 68Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients
- Intraoperative 68Ga-PSMA Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Feasibility Study
- Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study
- Diagnostic Value of 68Ga-PSMA PET/CT for Detection of Phosphatase and Tensin Homolog Expression in Prostate Cancer: A Pilot Study
- Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines
- Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?
- Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy
- Lymph Node Involvement in Treatment-Naive Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management
- Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
- Simplified Methods for Quantification of 18F-DCFPyL Uptake in Patients with Prostate Cancer
- Improving 68Ga-PSMA PET/MRI of the Prostate with Unrenormalized Absolute Scatter Correction
- Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence--A Narrative Review of the Literature
- Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging
- Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models
- Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer
- Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study
- Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence
- Synthesis and Binding of a Novel PSMA-specific Conjugate
- Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
- PSMA PET: Transformational Change in Prostate Cancer Management?
- 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning